Latest & greatest articles for copd exacerbations

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on copd exacerbations or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on copd exacerbations and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for copd exacerbations

41. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study Full Text available with Trip Pro

Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study Oxidative stress contributes to chronic obstructive pulmonary disease (COPD) exacerbations and antioxidants can decrease exacerbation rates, although we lack data about the effect of such drugs on exacerbation duration.The RESTORE (Reducing Exacerbations and Symptoms by Treatment with ORal Erdosteine in COPD) study was a prospective randomised, double-blind, placebo-controlled study, enrolling patients aged (...) 40-80 years with Global Initiative for Chronic Obstructive Lung Disease stage II/III. Patients received erdosteine 300 mg twice daily or placebo added to usual COPD therapy for 12 months. The primary outcome was the number of acute exacerbations during the study.In the pre-specified intention-to-treat population of 445 patients (74% male; mean age 64.8 years, forced expiratory volume in 1 s 51.8% predicted) erdosteine reduced the exacerbation rate by 19.4% (0.91 versus 1.13 exacerbations·patient

2018 EvidenceUpdates Controlled trial quality: predicted high

42. Comparisons of Exacerbations and Mortality Among Regular Inhaled Therapies for Patients with Stable Chronic Obstructive Pulmonary Disease: Systematic Review and Bayesian Network Meta-Analysis Full Text available with Trip Pro

shown different results for the treatment of stable chronic obstructive pulmonary disease (COPD). Additionally, outcomes other than symptoms and lung function have not been fully compared among regular inhaled therapies in a systematic review. In this systematic review and Bayesian network meta-analysis, we compared the risk of exacerbation, mortality, and other adverse events, including cardiovascular disease-related death and pneumonia, among regular inhaled drugs in patients with stable COPD (...) of Systematic Reviews (PROSPERO, CRD42017069087). Keywords: Pulmonary Disease, Chronic Obstructive; Respiratory Therapy; Administration, Inhalation; Symptom Flare-Up; Mortality; Drug-Related Side Effects and Adverse Reactions; Bayes Theorem; Network Meta-Analysis Suggested Citation: Lee, Hyun-Woo and Park, Jimyung and Jo, Junwoo and Jin Jang, Eun and Lee, Chang-Hoon, Comparisons of Exacerbations and Mortality Among Regular Inhaled Therapies for Patients with Stable Chronic Obstructive Pulmonary Disease

2018 SSRN Electronic Journal

43. Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline

on the management of #COPD exacerbations from @ERStalk and @atscommunity Executive summary Chronic obstructive pulmonary disease (COPD) exacerbations are episodes of increased respiratory symptoms, particularly dyspnoea, cough and sputum. The European Respiratory Society (ERS) and American Thoracic Society (ATS) collaborated to develop guidelines that address questions regarding the treatment of COPD exacerbations that are not clearly answered by current guidelines. Key recommendations from the guidelines (...) recommendation, very low quality of evidence). Introduction The chronic and progressive course of chronic obstructive pulmonary disease (COPD) is often punctuated by “exacerbations”, defined clinically as episodes of increasing respiratory symptoms, particularly dyspnoea, cough and sputum production, and increased sputum purulence. COPD exacerbations have a negative impact on the quality of life of patients with COPD [ , ], accelerate disease progression, and can result in hospital admissions and death

2017 European Respiratory Society

44. The Effect of Smartphone Interventions on Patients With Chronic Obstructive Pulmonary Disease Exacerbations: Systematic Review and Meta-Analysis Full Text available with Trip Pro

The Effect of Smartphone Interventions on Patients With Chronic Obstructive Pulmonary Disease Exacerbations: Systematic Review and Meta-Analysis Iproceedings - The Effect of Smartphone Interventions on Patients With Chronic Obstructive Pulmonary Disease Exacerbations: Systematic Review and Meta-Analysis Select options Resource Center Journal Information Browse Journal Year: Published on 22.9.2017 in The Effect of Smartphone Interventions on Patients With Chronic Obstructive Pulmonary Disease (...) Exacerbations: Systematic Review and Meta-Analysis The Effect of Smartphone Interventions on Patients With Chronic Obstructive Pulmonary Disease Exacerbations: Systematic Review and Meta-Analysis Authors of this article: ; ; ; ; ; ; ; ; ; ; Memorial University, St. John's, NL, Canada Corresponding Author: Meshari Alwashmi, BN, MSc Memorial University 230 Elizabeth Ave St. John's, NL, Canada Phone: Email: Keywords ; ; ; ; ; ; ; Edited by T Hale; This is a non–peer-reviewed article. submitted 05.07.17

2017 Iproceedings

45. Discontinuing noninvasive ventilation in severe chronic obstructive pulmonary disease exacerbations: a randomised controlled trial Full Text available with Trip Pro

Discontinuing noninvasive ventilation in severe chronic obstructive pulmonary disease exacerbations: a randomised controlled trial We assessed whether prolongation of nocturnal noninvasive ventilation (NIV) after recovery from acute hypercapnic respiratory failure (AHRF) in chronic obstructive pulmonary disease (COPD) patients with NIV could prevent subsequent relapse of AHRF.A randomised controlled trial was performed in 120 COPD patients without previous domiciliary ventilation, admitted (...) for AHRF and treated with NIV. When the episode was resolved and patients tolerated unassisted breathing for 4 h, they were randomly allocated to receive three additional nights of NIV (n=61) or direct NIV discontinuation (n=59). The primary outcome was relapse of AHRF within 8 days after NIV discontinuation.Except for a shorter median (interquartile range) intermediate respiratory care unit (IRCU) stay in the direct discontinuation group (4 (2-6) versus 5 (4-7) days, p=0.036), no differences were

2017 EvidenceUpdates

46. Home-based maintenance tele-rehabilitation reduces the risk for acute exacerbations of COPD, hospitalisations and emergency department visits Full Text available with Trip Pro

Home-based maintenance tele-rehabilitation reduces the risk for acute exacerbations of COPD, hospitalisations and emergency department visits Pulmonary rehabilitation (PR) remains grossly underutilised by suitable patients worldwide. We investigated whether home-based maintenance tele-rehabilitation will be as effective as hospital-based maintenance rehabilitation and superior to usual care in reducing the risk for acute chronic obstructive pulmonary disease (COPD) exacerbations (...) and hospital-based PR remained independent predictors of a lower risk for 1) acute COPD exacerbation (incidence rate ratio (IRR) 0.517, 95% CI 0.389-0.687, and IRR 0.635, 95% CI 0.473-0.853), respectively, and 2) hospitalisations for acute COPD exacerbation (IRR 0.189, 95% CI 0.100-0.358, and IRR 0.375, 95% CI 0.207-0.681), respectively. However, only home-based maintenance tele-rehabilitation and not hospital-based, outpatient, maintenance PR was an independent predictor of ED visits (IRR 0.116, 95% CI

2017 EvidenceUpdates

47. Colistin for Prophylactic Use in Non-Cystic Fibrosis Bronchiectasis or COPD with Exacerbations: A Review of Clinical and Cost-Effectiveness and Guidelines

the use of colistin for the prophylactic treatment of adults with either non-CF bronchiectasis or patients with COPD experiencing exacerbations. Tags copd, infection control, bronchiectasis, colistin, pulmonary disease, chronic obstructive, pulmonary emphysema, respiratory, colistimethate sodium, polymyxin E, Colisticin, chronic airflow obstruction, Chronic obstructive airway disease, Chronic obstructive lung disease, Chronic obstructive pulmonary disease, chronic bronchitis, emphysema, colomycin (...) pulmonary disease experiencing exacerbations? What is the cost-effectiveness of colistin for the prophylactic treatment of adults with either non-cystic fibrosis bronchiectasis or patients with chronic obstructive pulmonary disease experiencing exacerbations? What are the evidence-based guidelines associated with the use of colistin for the prophylactic treatment of adults with either non-cystic fibrosis bronchiectasis or patients with chronic obstructive pulmonary disease experiencing exacerbations

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

48. Effect of Home Noninvasive Ventilation With Oxygen Therapy vs Oxygen Therapy Alone on Hospital Readmission or Death After an Acute COPD Exacerbation: A Randomized Clinical Trial. Full Text available with Trip Pro

Effect of Home Noninvasive Ventilation With Oxygen Therapy vs Oxygen Therapy Alone on Hospital Readmission or Death After an Acute COPD Exacerbation: A Randomized Clinical Trial. Outcomes after exacerbations of chronic obstructive pulmonary disease (COPD) requiring acute noninvasive ventilation (NIV) are poor and there are few treatments to prevent hospital readmission and death.To investigate the effect of home NIV plus oxygen on time to readmission or death in patients with persistent (...) hypercapnia after an acute COPD exacerbation.A randomized clinical trial of patients with persistent hypercapnia (Paco2 >53 mm Hg) 2 weeks to 4 weeks after resolution of respiratory acidemia, who were recruited from 13 UK centers between 2010 and 2015. Exclusion criteria included obesity (body mass index [BMI] >35), obstructive sleep apnea syndrome, or other causes of respiratory failure. Of 2021 patients screened, 124 were eligible.There were 59 patients randomized to home oxygen alone (median oxygen

2017 JAMA Controlled trial quality: predicted high

49. Procalcitonin and CRP as Biomarkers in Discrimination of Community-acquired Pneumonia and Exacerbation of COPD Full Text available with Trip Pro

Procalcitonin and CRP as Biomarkers in Discrimination of Community-acquired Pneumonia and Exacerbation of COPD Serum procalcitonin (PCT) and C-reactive protein (CRP) are markers of systemic inflammation and bacterial infection. We aimed to compare the usefulness of procalcitonin and CRP in patients with community-acquired pneumonia and exacerbations of chronic obstructive pulmonary disease (COPD).A total of 116 consecutive patients were included in the study: 76 with chronic obstructive (...) pneumonia.Procalcitonin and CRP levels were significantly higher in patients with community-acquired pneumonia presenting to the emergency department with indications for hospitalization than in patients with exacerbations of chronic obstructive pulmonary disease. Serum CRP and procalcitonin concentrations were strongly correlated. CRP might be a more valuable marker in these patients with lower respiratory tract infections.

2017 Journal of medical biochemistry

50. Does Telehealth Monitoring Identify Exacerbations of Chronic Obstructive Pulmonary Disease and Reduce Hospitalisations? An Analysis of System Data Full Text available with Trip Pro

Does Telehealth Monitoring Identify Exacerbations of Chronic Obstructive Pulmonary Disease and Reduce Hospitalisations? An Analysis of System Data The increasing prevalence and associated cost of treating chronic obstructive pulmonary disease (COPD) is unsustainable. Health care organizations are focusing on ways to support self-management and prevent hospital admissions, including telehealth-monitoring services capturing physiological and health status data. This paper reports on data captured (...) during a pilot randomized controlled trial of telehealth-supported care within a community-based service for patients discharged from hospital following an exacerbation of their COPD.The aim was to undertake the first analysis of system data to determine whether telehealth monitoring can identify an exacerbation of COPD, providing clinicians with an opportunity to intervene with timely treatment and prevent hospital readmission.A total of 23 participants received a telehealth-supported intervention

2017 JMIR medical informatics Controlled trial quality: uncertain

51. β-blockers in exacerbations of COPD: feasibility of a randomised controlled trial. Full Text available with Trip Pro

β-blockers in exacerbations of COPD: feasibility of a randomised controlled trial. A feasibility randomised controlled trial of β-blockers in acute exacerbations of COPD http://ow.ly/lVcy305B36D.

2017 ERJ open research Controlled trial quality: uncertain

52. Prevention of COPD Exacerbations: An Official ERS/ATS Clinical Practice Guideline

provides clinical recommendations for the prevention of chronic obstructive pulmonary disease (COPD) exacerbations. It represents a collaborative effort between the European Respiratory Society and the American Thoracic Society. Comprehensive evidence syntheses were performed to summarise all available evidence relevant to the Task Force’s questions. The evidence was appraised using the Grading of Recommendations, Assessment, Development and Evaluation approach and the results were summarised (...) M, Hurst JR, et al. Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J 2017; 49: 1600791. 7 National Institute for Health and Clinical Excellence. Chronic obstructive pulmonary disease: management of chronic pulmonary obstructive disease in adults in primary and secondary care (partial update). London, National Clinical Guideline Centre, 2010. 8 Poole P, Chong J, Cates CJ. Mucolytic agents versus placebo for chronic bronchitis

2017 American Thoracic Society

53. Management of COPD Exacerbations: An Official ERS/ATS Clinical Practice Guideline

should be reconsidered as new evidence becomes available. Copyright ©ERS 2017 https://doi.org/10.1183/13993003.00791-2016 Eur Respir J 2017; 49: 1600791 TASK FORCE REPORT ERS/ATS GUIDELINEIntroduction The chronic and progressive course of chronic obstructive pulmonary disease (COPD) is often punctuated by “exacerbations”, defined clinically as episodes of increasing respiratory symptoms, particularly dyspnoea, cough and sputum production, and increased sputum purulence. COPD exacerbations have (...) -2016]. ABSTRACT This document provides clinical recommendations for treatment of chronic obstructive pulmonary disease (COPD) exacerbations. Comprehensive evidence syntheses, including meta-analyses, were performed to summarise all available evidence relevant to the Task Force’s questions. The evidence was appraised using the Grading of Recommendations, Assessment, Development and Evaluation approach and the results were summarised in evidence profiles. The evidence syntheses were discussed

2017 American Thoracic Society

54. In stable COPD, long-acting muscarinic antagonist plus long-acting beta-agonists resulted in less exacerbations, pneumonia and larger improvement in FEV 1 than long-acting beta-agonists plus inhaled corticosteroids

Mario Cazzola , Paola Rogliani Statistics from Altmetric.com Commentary on: Horita N, Goto A, Shibata Y, et al . Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev 2017;2:CD012066. Context The Global Initiative for Chronic Obstrictove Lung Disease 2017 report recommends the use of long-acting muscarinic antagonist (LAMA) + long-acting beta (...) -agonist (LABA), or alternatively LABA + inhaled corticosteroid (ICS), in patients with chronic obstructive pulmonary disease (COPD) at risk of exacerbations regardless of the entity of symptoms. 1 However, it does not specify whether it is preferable to start with LAMA+LABA rather than LABA+ICS. In fact, no firm conclusions can be drawn from the current literature. Methods The aim of this study was to compare the benefits and harms of LAMA+LABA versus LABA+ICS in the treatment of COPD. The authors

2017 Evidence-Based Medicine

55. The role of complement activation in COPD exacerbation recovery Full Text available with Trip Pro

The role of complement activation in COPD exacerbation recovery Rise in sputum complement (C3a, C5a) levels during COPD exacerbation is associated with recovery time http://ow.ly/ZaPj303xxPf.

2016 ERJ open research

56. A validation of the National Early Warning Score to predict outcome in patients with COPD exacerbation Full Text available with Trip Pro

A validation of the National Early Warning Score to predict outcome in patients with COPD exacerbation The National Early Warning Score (NEWS), proposed as a standardised track and trigger system, may perform less well in acute exacerbation of COPD (AECOPD). This study externally validated NEWS and modifications (Chronic Respiratory Early Warning Score (CREWS) and Salford-NEWS) in AECOPD.An observational cohort study (2012-2014, two UK acute medical units (AMUs)), compared AECOPD (2361 (...) found modest discrimination to predict mortality. Lower specificity of NEWS in patients with AECOPD versus other AMU patients reflects acute and chronic respiratory physiological disturbance (including hypoxia), with resultant low PPV at NEWS=5. CREWS and Salford-NEWS, adjusting for chronic hypoxia, increased the specificity and PPV but there was no gain in discrimination.Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go

2016 EvidenceUpdates

57. Pulmonary rehabilitation for acute exacerbations of chronic obstructive pulmonary disease (COPD): A systematic review Full Text available with Trip Pro

Pulmonary rehabilitation for acute exacerbations of chronic obstructive pulmonary disease (COPD): A systematic review Pulmonary rehabilitation for acute exacerbations of chronic obstructive pulmonary disease (COPD): A systematic review | European Respiratory Society Main menu User menu Search Search for this keyword Search for this keyword Pulmonary rehabilitation for acute exacerbations of chronic obstructive pulmonary disease (COPD): A systematic review Elizabeth Moore , Thomas Palmer , Roger (...) a message from European Respiratory Society Message Body (Your Name) thought you would like to see the European Respiratory Society web site. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. User Name * Password * Sign In to Email Alerts with your Email Address Email * Pulmonary rehabilitation for acute exacerbations of chronic obstructive pulmonary disease (COPD): A systematic review Elizabeth Moore , Thomas

2016 1.2 Rehabilitation and Chronic Care

58. Global associations between air pollutants and chronic obstructive pulmonary disease (COPD) exacerbations: A systematic review Full Text available with Trip Pro

Global associations between air pollutants and chronic obstructive pulmonary disease (COPD) exacerbations: A systematic review Global associations between air pollutants and chronic obstructive pulmonary disease (COPD) exacerbations: A systematic review | European Respiratory Society Main menu User menu Search Search for this keyword Search for this keyword Global associations between air pollutants and chronic obstructive pulmonary disease (COPD) exacerbations: A systematic review Elizabeth (...) ) thought you would like to see the European Respiratory Society web site. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. User Name * Password * Sign In to Email Alerts with your Email Address Email * Global associations between air pollutants and chronic obstructive pulmonary disease (COPD) exacerbations: A systematic review Elizabeth Moore , Lia Chatzidiakou , Moyosore-Oluwa Kuku , Roderic Jones , Liam Smeeth

2016 6.1 Epidemiology

59. The inflammasome pathway in stable COPD and acute exacerbations Full Text available with Trip Pro

The inflammasome pathway in stable COPD and acute exacerbations Chronic obstructive pulmonary disease (COPD) is characterised by pulmonary and systemic inflammation that bursts during exacerbations of the disease (ECOPD). The NLRP3 inflammasome is a key regulatory molecule of the inflammatory response. Its role in COPD is unclear. We investigated the NLRP3 inflammasome status in: 1) lung tissue samples from 38 patients with stable COPD, 15 smokers with normal spirometry and 14 never-smokers (...) ; and 2) sputum and plasma samples from 56 ECOPD patients, of whom 41 could be reassessed at clinical recovery. We observed that: 1) in lung tissue samples of stable COPD patients, NLRP3 and interleukin (IL)-1β mRNA were upregulated, but both caspase-1 and ASC were mostly in inactive form, and 2) during infectious ECOPD, caspase-1, oligomeric ASC and associated cytokines (IL-1β, IL-18) were significantly increased in sputum compared with clinical recovery. The NLRP3 inflammasome is primed

2016 ERJ open research

60. Another Choice for Prevention of COPD Exacerbations. Full Text available with Trip Pro

Another Choice for Prevention of COPD Exacerbations. 27181835 2016 06 21 2018 12 02 1533-4406 374 23 2016 Jun 09 The New England journal of medicine N. Engl. J. Med. Another Choice for Prevention of COPD Exacerbations. 2284-6 10.1056/NEJMe1604444 Donohue James F JF From the Division of Pulmonary Diseases and Critical Care Medicine, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill. eng Editorial Comment 2016 05 15 United States N Engl J Med 0255562 0028-4793 0 (...) Pulmonary Disease, Chronic Obstructive drug therapy Quinolones therapeutic use 2016 5 17 6 0 2016 5 18 6 0 2016 6 22 6 0 ppublish 27181835 10.1056/NEJMe1604444

2016 NEJM